Oncology · 2002 · 57 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeoplasiaChemotherapy ResistanceCytotoxic ChemotherapyMalignant NeoplasmsMalignant TumorsOvarian CancerTherapeutic ResistanceAnticancer Drug ResistanceCell Proliferation KineticsClear Cell NeoplasmsOvarian Cancer ChemotherapyPlatinum SensitivityPlatinum-based AgentsPopulation Doubling TimeTherapeutic Resistance Mechanisms
Resistance of clear cell carcinoma (CCC) of the ovary to platinum-based chemotherapy is associated with a poor prognosis. However, the mechanism underlying the resistance of CCC to platinum has not yet been understood. We conducted the present study to clarify the mechanism of cisplatin (CDDP) resistance in CCC cells. Eleven CCC and 5 serous adenocarcinoma (SAC) cell lines were used in this study. The IC(50) to CDDP ranged from 1.3 to 18.0 microM for CCC cells and from 2.2 to 13.0 microM for SAC cells. There was no correlation between multidrug resistance-associated protein expression and the sensitivity to CDDP in CCC cells. In contrast, the doubling time for CCC cells was significantly longer than that for SAC cells (61.4 vs. 29.8 h). A significant reverse correlation between the S-phase fraction and the response to CDDP was observed (r = 0.647, p < 0.05). The present study suggests that the resistance of CCC to CDDP may be caused by low cell proliferation.
29
Clinical characteristics of clear cell carcinoma of the ovary
Toru Sugiyama, Toshiharu Kamura, Junzo Kigawa et al. · Cancer · 2000 · 804 citations
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
Andrews Pa, Howell Sb · PubMed · 1990 · 401 citations
Medicine, Oncology, Pharmacology +16